Biomerica Stock Price, News & Analysis (NASDAQ:BMRA) $0.93 +0.03 (+3.33%) (As of 11/30/2023 ET) Add Compare Share Share Today's Range$0.89▼$0.9450-Day Range$0.71▼$1.0552-Week Range$0.70▼$4.04Volume6,514 shsAverage Volume97,140 shsMarket Capitalization$15.64 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media About Biomerica Stock (NASDAQ:BMRA)Biomerica, Inc., a biomedical technology company, develops, patents, manufactures, and markets diagnostic and therapeutic products for the detection and/or treatment of medical conditions and diseases worldwide. The company's diagnostic test kits are used to analyze blood, urine, nasal or fecal specimens from patients in the diagnosis of various diseases, food intolerances, and other medical complications; or to measure bacteria, hormones, antibodies, antigens, or other substances which may exist in the human body, stools, or blood in extremely small concentrations. It primarily sells its products for gastrointestinal diseases, food intolerances, and various esoteric tests at the physicians' offices and over-the-counter drugstores, and hospital/clinical laboratories. The company is also developing InFoods IBS, that uses a simple blood sample to identify patient-specific foods which may alleviate irritable bowel syndrome symptoms; and H. Pylori diagnostic test that indicates if a patient is infected with the H. Pylori bacteria. In addition, it develops products to indicate if a person has been infected by COVID-19. Biomerica, Inc. was incorporated in 1971 and is headquartered in Irvine, California.Read More BMRA Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart BMRA Stock News HeadlinesNovember 23, 2023 | americanbankingnews.comBiomerica (NASDAQ:BMRA) Stock Crosses Below 200 Day Moving Average of $1.19November 23, 2023 | americanbankingnews.comBiomerica (NASDAQ:BMRA) Share Price Crosses Below 200 Day Moving Average of $1.19November 30, 2023 | Autonomix (Ad)[Investor Alert] Potential Breakthrough Medical Tech Investment OpportunityAutonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.comNovember 10, 2023 | tmcnet.comBiomerica to Participate in 14th Annual Craig-Hallum Alpha Select Conference on November 16November 8, 2023 | finance.yahoo.comBiomerica Expands inFoods IBS Reach with Addition of Several New GI GroupsOctober 13, 2023 | markets.businessinsider.comREPEAT - Biomerica Reports First Quarter 2024 Financial ResultsOctober 13, 2023 | finanznachrichten.deBiomerica, Inc.: Biomerica Reports First Quarter 2024 Financial ResultsOctober 13, 2023 | markets.businessinsider.comBiomerica Reports First Quarter 2024 Financial ResultsNovember 30, 2023 | Tomorrow Investor (Ad)The Only Practical Solution to the World’s Looming Energy CrisisThere’s just one problem: There are more plans for new uses of nuclear than there is uranium to fuel the plants!September 26, 2023 | tmcnet.comDubai Government Grants Insurance Reimbursement for Biomerica's EZ Detect™ Colorectal Disease Screening TestSeptember 26, 2023 | finance.yahoo.comDubai Government Grants Insurance Reimbursement for Biomerica’s EZ Detect™ Colorectal Disease Screening TestAugust 28, 2023 | tmcnet.comDiagnostics Industry Leader Jack Kenny Joins Biomerica's Board of DirectorsAugust 27, 2023 | finance.yahoo.comBiomerica Full Year 2023 Earnings: US$0.50 loss per share (vs US$0.36 loss in FY 2022)August 26, 2023 | finanznachrichten.deBiomerica, Inc.: Biomerica Reports Fiscal 2023 Year End ResultsAugust 25, 2023 | msn.comBiomerica reports FY resultsAugust 25, 2023 | finance.yahoo.comBiomerica Reports Fiscal 2023 Year End ResultsAugust 3, 2023 | it.tmcnet.comCVS Health to Begin Nationwide In-Store Sales of Biomerica's EZ Detect™ Colorectal Disease Screening TestJune 21, 2023 | finance.yahoo.comBiomerica Receives Notice of Patent Allowance in China for a Potential Innovative Technology That Includes an Artificial Intelligence (AI) Claim for Predicting Foods That Contain Ingredients That Cause Adverse Reactions in PatientsMay 21, 2023 | seekingalpha.comQRTEA, BIOC and AMTX among mid-day moversMay 18, 2023 | it.tmcnet.cominFoods® IBS Test Now Validated for Use with Simple Finger Stick Whole Blood Collection TechnologyApril 17, 2023 | finance.yahoo.comBiomerica, Inc. (BMRA) Stock Historical Prices & Data - Yahoo FinanceApril 17, 2023 | finance.yahoo.comBiomerica’s inFoods® IBS test is now available at Gastro Health, providing a revolutionary new treatment for patients suffering from Irritable Bowel Syndrome (IBS).April 15, 2023 | finanznachrichten.deBiomerica, Inc.: Biomerica Reports Q3 Fiscal 2023 ResultsApril 14, 2023 | finance.yahoo.comBiomerica Reports Q3 Fiscal 2023 ResultsMarch 8, 2023 | finance.yahoo.comBiomerica announces the Launch of InFoods IBS as a Laboratory Developed Test (LDT); First patient samples have been processedMarch 7, 2023 | finance.yahoo.comBiomerica Announces Closing of $8 Million Underwritten Public Offering of Common StockMarch 3, 2023 | finance.yahoo.comBiomerica Announces Pricing of $8 Million Underwritten Public Offering of Common StockSee More Headlines Receive BMRA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Biomerica and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings10/12/2023Today11/30/2023Next Earnings (Estimated)1/12/2024Fiscal Year End5/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Diagnostic substances Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:BMRA CUSIPN/A CIK73290 Webwww.biomerica.com Phone(949) 645-2111Fax949-553-1231Employees62Year Founded1971Profitability EPS (Most Recent Fiscal Year)($0.41) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-7,140,000.00 Net Margins-114.52% Pretax Margin-113.19% Return on Equity-69.43% Return on Assets-54.16% Debt Debt-to-Equity RatioN/A Current Ratio6.63 Quick Ratio5.55 Sales & Book Value Annual Sales$5.34 million Price / Sales2.90 Cash FlowN/A Price / Cash FlowN/A Book Value$0.70 per share Price / Book1.31Miscellaneous Outstanding Shares16,820,000Free Float14,551,000Market Cap$15.47 million OptionableNot Optionable Beta-0.64 Social Links 20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free Report Key ExecutivesMr. Zackary S. Irani (Age 57)Chairman & CEO Comp: $141.25kMr. Allen C. Barbieri (Age 65)Executive Vice-Chairman of the Board & Corporate Secretary Comp: $126.25kMr. Gary Lu CPA (Age 42)Principal Accounting Officer & CFO Comp: $260kMs. Lucy Liu Ph.D.Director of Manufacturing & Technical OperationsHans BoehringerSenior Vice President of POC Research & DevelopmentMr. Robert W. CarlsonChief Commercial OfficerMore ExecutivesKey CompetitorsMyMD PharmaceuticalsNASDAQ:MYMDTrinity BiotechNASDAQ:TRIBNavidea BiopharmaceuticalsNYSE:NAVBAspira Women's HealthNASDAQ:AWHOncoCyteNASDAQ:OCXView All CompetitorsInsiders & InstitutionsPotomac Capital Management Inc.Sold 231,397 shares on 11/14/2023Ownership: 1.020%Zackary S IraniBought 500 shares on 5/24/2023Total: $805.00 ($1.61/share)Zackary S IraniBought 1,700 shares on 5/12/2023Total: $1,989.00 ($1.17/share)Zackary S IraniBought 300 shares on 5/9/2023Total: $417.00 ($1.39/share)Zackary S IraniBought 1,800 shares on 4/28/2023Total: $2,412.00 ($1.34/share)View All Insider TransactionsView All Institutional Transactions BMRA Stock Analysis - Frequently Asked Questions How have BMRA shares performed in 2023? Biomerica's stock was trading at $3.35 at the beginning of the year. Since then, BMRA shares have decreased by 72.2% and is now trading at $0.93. View the best growth stocks for 2023 here. Are investors shorting Biomerica? Biomerica saw a decline in short interest during the month of November. As of November 15th, there was short interest totaling 360,100 shares, a decline of 13.0% from the October 31st total of 414,100 shares. Based on an average daily volume of 53,600 shares, the days-to-cover ratio is presently 6.7 days. View Biomerica's Short Interest. When is Biomerica's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Friday, January 12th 2024. View our BMRA earnings forecast. How were Biomerica's earnings last quarter? Biomerica, Inc. (NASDAQ:BMRA) announced its quarterly earnings data on Thursday, October, 12th. The company reported ($0.07) EPS for the quarter. The company had revenue of $1.71 million for the quarter. Biomerica had a negative net margin of 114.52% and a negative trailing twelve-month return on equity of 69.43%. What other stocks do shareholders of Biomerica own? Based on aggregate information from My MarketBeat watchlists, some companies that other Biomerica investors own include Sorrento Therapeutics (SRNE), Pfizer (PFE), Johnson & Johnson (JNJ), OPKO Health (OPK), TG Therapeutics (TGTX), Advanced Micro Devices (AMD), Co-Diagnostics (CODX), FuelCell Energy (FCEL) and Trevena (TRVN). Who are Biomerica's major shareholders? Biomerica's stock is owned by a variety of retail and institutional investors. Top institutional investors include Potomac Capital Management Inc. (1.02%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Allen Barbieri, Catherine Coste and Zackary S Irani. View institutional ownership trends. How do I buy shares of Biomerica? Shares of BMRA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. This page (NASDAQ:BMRA) was last updated on 11/30/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Biomerica, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.